Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

References

• Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176:346 - 56; PMID: 16365427
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281:23514 - 24; http://dx.doi.org/10.1074/jbc.M604292200; PMID: 16793771
   PubMed Web of Science ®Google Scholar
• Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008; 20:460 - 70; http://dx.doi.org/10.1016/j.coi.2008.06.012; PMID: 18656541
   PubMed Web of Science ®Google Scholar
• Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182:7663 - 71; http://dx.doi.org/10.4049/jimmunol.0804182; PMID: 19494290
   PubMed Web of Science ®Google Scholar
• Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009; 100:1566 - 72; http://dx.doi.org/10.1111/j.1349-7006.2009.01222.x; PMID: 19538497
   PubMed Web of Science ®Google Scholar
• Nixon AE, Wood CR. Engineered protein inhibitors of proteases. Curr Opin Drug Discov Devel 2006; 9:261 - 8; PMID: 16566296
   PubMed Web of Science ®Google Scholar
• Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 2007; 352:95 - 109; PMID: 17041261
   PubMedGoogle Scholar
• Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008; 275:2668 - 76; http://dx.doi.org/10.1111/j.1742-4658.2008.06438.x; PMID: 18435759
   PubMed Web of Science ®Google Scholar
• Skerra A. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 2008; 275:2677 - 83; http://dx.doi.org/10.1111/j.1742-4658.2008.06439.x; PMID: 18435758
   PubMed Web of Science ®Google Scholar
• Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today 2008; 13:695 - 701; http://dx.doi.org/10.1016/j.drudis.2008.04.013; PMID: 18621567
   PubMed Web of Science ®Google Scholar
• Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995; 374:168 - 73; http://dx.doi.org/10.1038/374168a0; PMID: 7877689
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363:446 - 8; http://dx.doi.org/10.1038/363446a0; PMID: 8502296
   PubMed Web of Science ®Google Scholar
• Obeidat M, Obeidat M, Ballermann BJ. Glomerular endothelium: a porous sieve and formidable barrier. Exp Cell Res 2012; 318:964 - 72; http://dx.doi.org/10.1016/j.yexcr.2012.02.032; PMID: 22465480
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22:868 - 76; http://dx.doi.org/10.1016/j.copbio.2011.06.012; PMID: 21862310
   PubMed Web of Science ®Google Scholar
• Pedley RB, Boden JA, Boden R, Begent RH, Turner A, Haines AM, et al. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody. Br J Cancer 1994; 70:1126 - 30; http://dx.doi.org/10.1038/bjc.1994.459; PMID: 7981064
   PubMed Web of Science ®Google Scholar
• Kitamura K, Takahashi T, Yamaguchi T, Noguchi A, Noguchi A, Takashina K, et al. Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 1991; 51:4310 - 5; PMID: 1868453
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17:780 - 3; http://dx.doi.org/10.1038/11717; PMID: 10429243
   PubMed Web of Science ®Google Scholar
• Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010; 5:113 - 28; http://dx.doi.org/10.1002/biot.200900218; PMID: 20069580
   PubMed Web of Science ®Google Scholar
• Stork R, Zettlitz KA, Müller D, Rether M, Hanisch FG, Kontermann RE. N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem 2008; 283:7804 - 12; http://dx.doi.org/10.1074/jbc.M709179200; PMID: 18211902
   PubMed Web of Science ®Google Scholar
• Alt M, Müller R, Kontermann RE. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999; 454:90 - 4; http://dx.doi.org/10.1016/S0014-5793(99)00782-6; PMID: 10413102
   PubMed Web of Science ®Google Scholar
• Peters T Jr.. Serum albumin. Adv Protein Chem 1985; 37:161 - 245; http://dx.doi.org/10.1016/S0065-3233(08)60065-0; PMID: 3904348
   PubMedGoogle Scholar
• Wunder A, Müller-Ladner U, Stelzer EH, Funk J, Neumann E, Stehle G, et al. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003; 170:4793 - 801; PMID: 12707361
   PubMed Web of Science ®Google Scholar
• Fiehn C, Müller-Ladner U, Gay S, Krienke S, Freudenberg-Konrad S, Funk J, et al. Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 2004; 43:1097 - 105; http://dx.doi.org/10.1093/rheumatology/keh254; PMID: 15199219
   PubMed Web of Science ®Google Scholar
• Stehle G, Sinn H, Wunder A, Schrenk HH, Stewart JC, Hartung G, et al. Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997; 26:77 - 100; http://dx.doi.org/10.1016/S1040-8428(97)00015-2; PMID: 9298326
   PubMed Web of Science ®Google Scholar
• Wunder A, Stehle G, Sinn H, Schrenk H, Hoffbiederbeck D, Bader F, et al. Enhanced albumin uptake by rat tumors. Int J Oncol 1997; 11:497 - 507; PMID: 21528238
   PubMed Web of Science ®Google Scholar
• Wunder A, Stehle G, Schrenk HH, Hartung G, Heene DL, Maier-Borst W, et al. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int J Cancer 1998; 76:884 - 90; http://dx.doi.org/10.1002/(SICI)1097-0215(19980610)76:6<884::AID-IJC19>3.0.CO;2-2; PMID: 9626357
   PubMed Web of Science ®Google Scholar
• Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasawara A, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007; 67:254 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-06-2531; PMID: 17210705
   PubMed Web of Science ®Google Scholar
• Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7:2288 - 97; http://dx.doi.org/10.1158/1535-7163.MCT-07-2384; PMID: 18723476
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003; 197:315 - 22; http://dx.doi.org/10.1084/jem.20021829; PMID: 12566415
   PubMed Web of Science ®Google Scholar
• Smith BJ, Popplewell A, Athwal D, Chapman AP, Heywood S, West SM, et al. Prolonged in vivo residence times of antibody fragments associated with albumin. Bioconjug Chem 2001; 12:750 - 6; http://dx.doi.org/10.1021/bc010003g; PMID: 11562193
   PubMed Web of Science ®Google Scholar
• Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995; 312:725 - 31; PMID: 8554512
   PubMed Web of Science ®Google Scholar
• Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrøm J, Hasselager E, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39:281 - 8; http://dx.doi.org/10.1007/BF00418343; PMID: 8721773
   PubMed Web of Science ®Google Scholar
• Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650 - 60; http://dx.doi.org/10.1074/jbc.M700820200; PMID: 17347147
   PubMed Web of Science ®Google Scholar
• Makrides SC, Nygren PA, Andrews B, Ford PJ, Evans KS, Hayman EG, et al. Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 1996; 277:534 - 42; PMID: 8613964
   PubMed Web of Science ®Google Scholar
• Stork R, Müller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 2007; 20:569 - 76; http://dx.doi.org/10.1093/protein/gzm061; PMID: 17982179
   PubMed Web of Science ®Google Scholar
• Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002; 277:35035 - 43; http://dx.doi.org/10.1074/jbc.M205854200; PMID: 12119302
   PubMed Web of Science ®Google Scholar
• Nguyen A, Reyes AE 2nd, Zhang M, McDonald P, Wong WL, Damico LA, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006; 19:291 - 7; http://dx.doi.org/10.1093/protein/gzl011; PMID: 16621915
   PubMed Web of Science ®Google Scholar
• Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008; 21:283 - 8; http://dx.doi.org/10.1093/protein/gzm067; PMID: 18387938
   PubMed Web of Science ®Google Scholar
• Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006; 54:1856 - 66; http://dx.doi.org/10.1002/art.21827; PMID: 16736523
   PubMed Web of Science ®Google Scholar
• Smith LE, Crouch K, Cao W, Müller MR, Wu L, Steven J, et al. Characterization of the immunoglobulin repertoire of the spiny dogfish (Squalus acanthias). Dev Comp Immunol 2012; 36:665 - 79; http://dx.doi.org/10.1016/j.dci.2011.10.007; PMID: 22040740
   PubMed Web of Science ®Google Scholar
• Barelle C, Gill DS, Charlton K. Shark novel antigen receptors--the next generation of biologic therapeutics?. Adv Exp Med Biol 2009; 655:49 - 62; http://dx.doi.org/10.1007/978-1-4419-1132-2_6; PMID: 20047035
   PubMed Web of Science ®Google Scholar
• Dooley H, Flajnik MF, Porter AJ. Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display. Mol Immunol 2003; 40:25 - 33; http://dx.doi.org/10.1016/S0161-5890(03)00084-1; PMID: 12909128
   PubMed Web of Science ®Google Scholar
• Dooley H, Flajnik MF. Shark immunity bites back: affinity maturation and memory response in the nurse shark, Ginglymostoma cirratum. Eur J Immunol 2005; 35:936 - 45; http://dx.doi.org/10.1002/eji.200425760; PMID: 15688348
   PubMed Web of Science ®Google Scholar
• Dooley H, Stanfield RL, Brady RA, Flajnik MF. First molecular and biochemical analysis of in vivo affinity maturation in an ectothermic vertebrate. Proc Natl Acad Sci U S A 2006; 103:1846 - 51; http://dx.doi.org/10.1073/pnas.0508341103; PMID: 16446445
   PubMed Web of Science ®Google Scholar
• Liu JL, Anderson GP, Goldman ER. Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library. BMC Biotechnol 2007; 7:78; http://dx.doi.org/10.1186/1472-6750-7-78; PMID: 18021450
   PubMed Web of Science ®Google Scholar
• Liu JL, Anderson GP, Delehanty JB, Baumann R, Hayhurst A, Goldman ER. Selection of cholera toxin specific IgNAR single-domain antibodies from a naïve shark library. Mol Immunol 2007; 44:1775 - 83; http://dx.doi.org/10.1016/j.molimm.2006.07.299; PMID: 17007931
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Krishnan UV, Hattarki M, De Gori R, Irving RA, Hudson PJ. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 2001; 38:313 - 26; http://dx.doi.org/10.1016/S0161-5890(01)00057-8; PMID: 11566324
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Krishnan UV, Doughty L, Nathanielsz A, Ally N, Pike RN, et al. A naturally occurring NAR variable domain binds the Kgp protease from Porphyromonas gingivalis. FEBS Lett 2002; 516:80 - 6; http://dx.doi.org/10.1016/S0014-5793(02)02506-1; PMID: 11959108
   PubMed Web of Science ®Google Scholar
• Nuttall SD, Humberstone KS, Krishnan UV, Carmichael JA, Doughty L, Hattarki M, et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 2004; 55:187 - 97; http://dx.doi.org/10.1002/prot.20005; PMID: 14997552
   PubMed Web of Science ®Google Scholar
• Shao CY, Secombes CJ, Porter AJ. Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library. Mol Immunol 2007; 44:656 - 65; http://dx.doi.org/10.1016/j.molimm.2006.01.010; PMID: 16500706
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36:3044 - 51; http://dx.doi.org/10.1002/eji.200636556; PMID: 17048273
   PubMed Web of Science ®Google Scholar
• Carter DC, Ho JX. Structure of serum albumin. Adv Protein Chem 1994; 45:153 - 203; http://dx.doi.org/10.1016/S0065-3233(08)60640-3; PMID: 8154369
   PubMedGoogle Scholar
• Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng 1999; 12:439 - 46; http://dx.doi.org/10.1093/protein/12.6.439; PMID: 10388840
   PubMedGoogle Scholar
• Chaudhury C, Brooks CL, Carter DC, Robinson JM, Anderson CL. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Biochemistry 2006; 45:4983 - 90; http://dx.doi.org/10.1021/bi052628y; PMID: 16605266
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Commun 2012; 3:610; http://dx.doi.org/10.1038/ncomms1607; PMID: 22215085
   PubMed Web of Science ®Google Scholar
• Seymour LW, Duncan R, Strohalm J, Kopecek J. Effect of molecular weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J Biomed Mater Res 1987; 21:1341 - 58; http://dx.doi.org/10.1002/jbm.820211106; PMID: 3680316
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126 - 36; http://dx.doi.org/10.1038/nbt1142; PMID: 16151406
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26:1 - 9; http://dx.doi.org/10.1111/j.1745-7254.2005.00008.x; PMID: 15659107
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009; 1:128 - 41; http://dx.doi.org/10.4161/mabs.1.2.7631; PMID: 20061822
   PubMed Web of Science ®Google Scholar
• Cuesta ÁM, Sainz-Pastor N, Bonet J, Oliva B, Álvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol 2010; 28:355 - 62; http://dx.doi.org/10.1016/j.tibtech.2010.03.007; PMID: 20447706
   PubMed Web of Science ®Google Scholar
• Müller MR, O’Dwyer R, Kovaleva M, Rudkin F, Dooley H, Barelle CJ. Generation and isolation of target-specific single-domain antibodies from shark immune repertoires. Methods Mol Biol 2012; 907:177 - 94; PMID: 22907351
   PubMedGoogle Scholar
• Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, et al. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions. J Mol Biol 2009; 388:541 - 58; http://dx.doi.org/10.1016/j.jmb.2009.03.019; PMID: 19285987
   PubMed Web of Science ®Google Scholar
• Cummins E, Luxenberg DP, McAleese F, Widom A, Fennell BJ, Darmanin-Sheehan A, et al. A simple high-throughput purification method for hit identification in protein screening. J Immunol Methods 2008; 339:38 - 46; http://dx.doi.org/10.1016/j.jim.2008.07.016; PMID: 18760282
   PubMed Web of Science ®Google Scholar
• Huh SH, Do HJ, Lim HY, Kim DK, Choi SJ, Song H, et al. Optimization of 25 kDa linear polyethylenimine for efficient gene delivery. Biologicals 2007; 35:165 - 71; http://dx.doi.org/10.1016/j.biologicals.2006.08.004; PMID: 17084092
   PubMed Web of Science ®Google Scholar
• Backliwal G, Hildinger M, Hasija V, Wurm FM. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 2008; 99:721 - 7; http://dx.doi.org/10.1002/bit.21596; PMID: 17680657
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci 2010; 99:1028 - 45; PMID: 19569059
   PubMed Web of Science ®Google Scholar